Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Richard S. Geary sold 8,268 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, October 13th. The stock was sold at an average price of $60.00, for a total value of $496,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Ionis Pharmaceuticals, Inc. (IONS) traded up 0.56% during trading on Thursday, hitting $54.32. The stock had a trading volume of 1,264,066 shares. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $65.51. The stock has a 50 day moving average price of $56.64 and a 200-day moving average price of $50.99. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of 261.15 and a beta of 3.12.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. During the same period in the prior year, the firm earned ($0.47) earnings per share. The firm’s revenue for the quarter was up 170.7% compared to the same quarter last year. On average, equities research analysts predict that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/26/ionis-pharmaceuticals-inc-ions-svp-sells-496080-00-in-stock.html.
Several equities research analysts have recently issued reports on IONS shares. Evercore ISI initiated coverage on Ionis Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $65.00 price target for the company. Stifel Nicolaus reaffirmed a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 12th. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $18.00 price target (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, August 10th. Finally, Barclays PLC decreased their price target on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research note on Thursday, September 21st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $50.04.
A number of institutional investors have recently modified their holdings of IONS. UBS Asset Management Americas Inc. increased its position in Ionis Pharmaceuticals by 3.5% in the 1st quarter. UBS Asset Management Americas Inc. now owns 318,360 shares of the company’s stock valued at $12,798,000 after buying an additional 10,877 shares in the last quarter. Karp Capital Management Corp bought a new stake in Ionis Pharmaceuticals during the 1st quarter worth approximately $687,000. Parametric Portfolio Associates LLC increased its holdings in Ionis Pharmaceuticals by 8.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 99,863 shares of the company’s stock worth $4,014,000 after purchasing an additional 7,776 shares in the last quarter. Prudential Financial Inc. increased its holdings in Ionis Pharmaceuticals by 36.4% during the 1st quarter. Prudential Financial Inc. now owns 8,241 shares of the company’s stock worth $331,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Teachers Advisors LLC increased its holdings in Ionis Pharmaceuticals by 6.3% during the 1st quarter. Teachers Advisors LLC now owns 131,656 shares of the company’s stock worth $5,293,000 after purchasing an additional 7,846 shares in the last quarter. 89.21% of the stock is owned by institutional investors and hedge funds.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.